Tag: PropheSee
CCS sees AI tool as next step in diabetes care evolution
June 21, 2024Theresa Flaherty, Managing Editor
DALLAS – The volume of data being collected from diabetes patients presents an opportunity to use artificial intelligence to better understand which patients are at risk for non-adherence to therapy, says Richard Mackey, chief technology officer at CCS, which recently launched PropheSee, an AI-powered predictive model for CGM users.
“We want to deliver insights that help them anticipate whatever needs they might have (and identify) situations where some additional support or...
In brief: CCS launches PropheSee, Vertess’ Smith recognized
June 12, 2024HME News Staff
DALLAS – CCS has launched PropheSee, an AI-powered predictive model for health care organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.
With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk...
CCS Launches AI-powered model
June 11, 2024HME News Staff
DALLAS – CCS has launched PropheSee, an AI-powered predictive model for healthcare organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.
With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk classification,...